Jane Street
PLX icon

Jane Street’s Protalix BioTherapeutics PLX Stock Holding History

Jane Street’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.6K Sell
17,342
-272,575
-94% -$676K ﹤0.01% 11060
2025
Q4 		$522K Buy
+289,917
New +$593K ﹤0.01% 7585
2025
Q2 		– Sell
-294,318
Closed -$753K – 10580
2025
Q1 		$753K Buy
294,318
+180,702
+159% +$432K ﹤0.01% 6094
2024
Q4 		$214K Buy
113,616
+67,664
+147% +$95.7K ﹤0.01% 8309
2024
Q3 		$46.9K Sell
45,952
-244,307
-84% -$257K ﹤0.01% 9189
2024
Q2 		$340K Buy
290,259
+261,338
+904% +$309K ﹤0.01% 7613
2024
Q1 		$36.4K Buy
28,921
+96
+0.3% +$143 ﹤0.01% 8808
2023
Q4 		$51.3K Buy
+28,825
New +$44.8K ﹤0.01% 8772
2023
Q3 		– Sell
-276,082
Closed -$496K – 9198
2023
Q2 		$552K Buy
276,082
+236,417
+596% +$563K ﹤0.01% 6165
2023
Q1 		$83.3K Sell
39,665
-52,554
-57% -$92.2K ﹤0.01% 8303
2022
Q4 		$126K Buy
92,219
+13,743
+18% +$15.1K ﹤0.01% 7974
2022
Q3 		$82K Sell
78,476
-5,080
-6% -$5.63K ﹤0.01% 8742
2022
Q2 		$91K Sell
83,556
-61,652
-42% -$72.1K ﹤0.01% 8688
2022
Q1 		$154K Buy
145,208
+59,550
+70% +$54.6K ﹤0.01% 9212
2021
Q4 		$71K Buy
85,658
+44,709
+109% +$46.8K ﹤0.01% 9388
2021
Q3 		$54K Buy
40,949
+9,284
+29% +$14.1K ﹤0.01% 9527
2021
Q2 		$60K Sell
31,665
-16,663
-34% -$57.3K ﹤0.01% 9457
2021
Q1 		$215K Buy
48,328
+26,110
+118% +$122K ﹤0.01% 8168
2020
Q4 		$81K Buy
22,218
+7,557
+52% +$27.1K ﹤0.01% 7253
2020
Q3 		$57K Sell
14,661
-129,160
-90% -$467K ﹤0.01% 6893
2020
Q2 		$542K Buy
143,821
+93,469
+186% +$320K ﹤0.01% 4962
2020
Q1 		$124K Buy
50,352
+17,528
+53% +$58K ﹤0.01% 4858
2019
Q4 		$105K Buy
32,824
+31,291
+2,041% +$77.1K ﹤0.01% 4845
2019
Q3 		$3K Sell
1,533
-1,420
-48% -$4.24K ﹤0.01% 4983
2019
Q2 		$14K Buy
+2,953
New +$12.5K ﹤0.01% 5030
2019
Q1 		– Sell
-7,871
Closed -$24K – 5483
2018
Q4 		$24K Buy
7,871
+2,190
+39% +$10.4K ﹤0.01% 4778
2018
Q3 		$41K Buy
5,681
+1,174
+26% +$5.89K ﹤0.01% 4940
2018
Q2 		$19K Buy
4,507
+877
+24% +$3.9K ﹤0.01% 4867
2018
Q1 		$20K Sell
3,630
-153
-4% -$1.01K ﹤0.01% 4716
2017
Q4 		$25K Sell
3,783
-707
-16% -$4.77K ﹤0.01% 4467
2017
Q3 		$26K Sell
4,490
-2,359
-34% -$15.1K ﹤0.01% 4348
2017
Q2 		$57K Sell
6,849
-11,868
-63% -$111K ﹤0.01% 4221
2017
Q1 		$255K Sell
18,717
-20,059
-52% -$180K ﹤0.01% 3615
2016
Q4 		$173K Buy
38,776
+37,397
+2,712% +$167K ﹤0.01% 3775
2016
Q3 		$8K Buy
1,379
+18
+1% +$112 ﹤0.01% 3921
2016
Q2 		$9K Sell
1,361
-2,509
-65% -$20.1K ﹤0.01% 3991
2016
Q1 		$33K Sell
3,870
-10,293
-73% -$88.2K ﹤0.01% 3969
2015
Q4 		$144K Buy
14,163
+10,012
+241% +$102K ﹤0.01% 3715
2015
Q3 		$49K Sell
4,151
-8,021
-66% -$127K ﹤0.01% 3438
2015
Q2 		$237K Buy
12,172
+10,677
+714% +$222K ﹤0.01% 3089
2015
Q1 		$27K Sell
1,495
-3,445
-70% -$67.4K ﹤0.01% 3051
2014
Q4 		$91K Buy
4,940
+1,535
+45% +$33K ﹤0.01% 2343
2014
Q3 		$82K Buy
3,405
+1,962
+136% +$56.5K ﹤0.01% 2378
2014
Q2 		$53K Buy
1,443
+367
+34% +$14.8K ﹤0.01% 2420
2014
Q1 		$49K Buy
1,076
+3
+0.3% +$140 ﹤0.01% 2587
2013
Q4 		$42K Buy
+1,073
New +$45.2K ﹤0.01% 2246
2013
Q3 		– Sell
-1,298
Closed -$64K – 3018
2013
Q2 		$64K Buy
+1,298
New +$68.9K ﹤0.01% 2506

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Jane Street's PLX Position: Q1 2026 in Review

Jane Street reduced its Protalix BioTherapeutics (PLX) stake by 94% in Q1 2026, selling an estimated $676K and leaving 17,342 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #11060.

Jane Street first reported a position in PLX in Q2 2013 and has held it in 47 quarters since. The position peaked at $753K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Jane Street held 17,342 shares of Protalix BioTherapeutics worth $37.6K as of Q1 2026.
  • Jane Street sold 272,575 Protalix BioTherapeutics shares in Q1 2026, an estimated $676K.
  • Protalix BioTherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11060 holding.
  • Jane Street first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 47 quarters since.
  • Jane Street's Protalix BioTherapeutics position peaked at $753K in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.